Summary Oxaliplatin, the first available diaminocyclohexane platinum, has clinical activity in colorectal and ovarian cancers. Its mechanism of action is thought to be similar to that of cisplatin, its main mechanism being the intrastrand DNA adduct between two adjacent guanins or two adjacent guanine and adenine adducts. Ongoing molecular pharmacological studies of the mechanism of action of cisplatin suggest that platinated adducts are recognized by proteins of the mismatch repair system, including the products of the hMLH1 and hMSH2 genes. DNA mismatch repair defects occur in a wide variety of sporadic human cancers, are the main genetic factor in hereditary non-polyposis colon cancer and a frequent de novo or acquired phenomenon in ovarian cancer and other solid tumours. Moreover, they have recently been reported to be a cause of resistance to cisplatin but not to oxaliplatin, as diaminocyclohexane platinum adducts do not appear to be recognized by the mismatch repair complex. These findings explain the oxaliplatin activity in some cisplatin-resistant tumours. In addition, the good safety profile of oxaliplatin makes it a drug of choice for combination therapy, and it has been shown to be synergistic with other cytotoxic agents, including 5-fluorouracil, cisplatin, carboplatin, topotecan, gemcitabine and CPT-11. The results of several ongoing trials are awaited, but available data demonstrate that oxaliplatin is highly effective in the treatment of advanced colorectal and ovarian cancers. Promising early results suggest that it is also efficacious in non-Hodgkin's lymphoma, breast and non-small-cell lung cancers. As a result of its mechanism of action, its favourable safety profile and the differential profile of its antitumoral activity, the full potential of oxaliplatin as an active, versatile antitumoral agent is yet to be fully explored.
Oxaliplatin is a new diaminocyclohexane (DACH) platinum agent that has non-cross-resistant characteristics with cisplatin and carboplatin. It has been found to have a wide spectrum of activity and has proved effective in colorectal cancer as first-line therapy (Becouarn et Giacchetti et al, 1997) and in 5-fluorouracil (5-FU)-refractory tumours al, 1997) , in advanced ovarian cancer as first-line treatment and also in pretreated cancers (Extra et al, 1990) .
This new platinum derivative has an oxalate, which is the hydrolysable ligand, and DACH, the non-leaving carrier ligand. Like cisplatin, it acts as an alkylating agent on the DNA, forming mainly platinated intrastrand links with two adjacent guanine or two adjacent guanine and adenine adducts (Fink et al, 1997 ) (see Figure 1 ). It is more potent than cisplatin, however, requiring fewer DNA adducts to achieve an equal level of cytotoxicity.
The difference between cisplatin and oxaliplatin is thought to be the result of their varying effects on the mechanisms of resistance rather than a fundamental difference in their modes of action. Generally speaking, for all platinum compounds, there are six ways in which a cell can become resistant to their effects (Gately and Howell, 1993) . There may be a decrease in the accumulation of the drug, or an increased efflux, both of which lead to a decrease in intracellular concentrations of the compound. There may be increased inactivation within the cell, or an increase in the quenching of monoadducts. Finally, there could be an increase in excision repair or an increase in post-replication repair/defect in mismatch repair. These mechanisms are outlined in Figure 2 . In humans, there are at least five genes known to participate in the mismatch repair process: hMLH1, hMSH2, hPMS 1, hPMS2 and GT-binding protein/p 160. Defects in the repair system lead to a general instability and an increase in DNA lesions. Germ-line mutations in four of these genes lead to microsatellite instability.
Defects in hMLH 1 and/or hMSH2 are known to cause 15-20% of all cases of colorectal cancer. Furthermore, loss of the DNA mismatch repair system occurs in a wide variety of sporadic human cancers; it is a predisposing factor in hereditary nonpolyposis colorectal cancer, and is a frequent de novo or acquired phenomenon in ovarian cancer (Brown et al, 1997) .
Ongoing molecular pharmacological studies of the mechanism of action of cisplatin and carboplatin suggest that platinated adducts are recognized by proteins of the mismatch repair system, including the products of the hMLHI and hMSH2 genes. Loss of the mismatch repair system will therefore result in resistance to cisplatin and carboplatin. Exposure to cisplatin has been proved to select cellular populations with deficiencies in mismatch repair (Fink et al, 1997) .
In contrast to cisplatin, oxaliplatin adducts do not appear to be well recognized by the repair protein complex. Consequently, loss of this repair function does not affect the apoptotic response of the cell to oxaliplatin. These observations imply that oxaliplatin is selectively active in tumours exhibiting aberrancies of mismatch repair, which are a cause of resistance to the traditional platin agents. Indeed, with the lack of cross-resistance between cisplatin and oxaliplatin, cisplatin-resistant tumours may well respond to oxaliplatin. Oxaliplatin has been shown to be synergistic with other compounds, including cisplatin, carboplatin, CPT-11, topotecan and gemcitabine (Mathe et al, 1989; Alvarez et al, 1994; Ortuzar et al, 1994; Rixe et al, 1996; Brown et al, 1997; Raymond et al, 1997; Zeghari-Squalli et From Chollet et al (1996) .
In 25 patients with ovarian cancer, who had previously been heavily treated with cisplatin/carboplatin, oxaliplatin at a dose of 130 mg m-2 was combined with cisplatin at a dose of 100 mg m-2, each given every 3 weeks (Soulie et al, 1997) . The results (shown in Table 1 ) indicate an overall response rate of 40%.
One EORTC ongoing phase II trial is comparing the effectiveness of oxaliplatin (130 mg m-2) with that of taxol (175 mg m-2 i.v. for 3 h) in patients with platinum-refractory advanced ovarian cancer. Another multicentre phase II trial in France is investigating the effectiveness of oxaliplatin (130 mg m-2) as monotherapy in pretreated advanced ovarian cancer (Dieras et al, 1998) . The results of both studies should be available in 1998. Planned studies include combinations of oxaliplatin with topotecan (phase I), with taxol and cisplatin (phase II) and with taxol vs carboplatin and taxol (phase 11111).
NEW COMBINATIONS IN GASTROINTESTINAL CANCERS
A recent phase I trial has been carried out, in which oxaliplatin was combined with CPT-11 in the treatment of advanced digestive cancers (colorectal, gastric, pancreatic, hepatic, biliary tract, oesophageal) (Cvitkovic et al, 1997). Oxaliplatin was given as a 2-h i.v. infusion; 1 h after this had been completed, CPT-11 was given as a 30-min i.v. infusion. The treatment schedule was repeated every 3 weeks, with escalating doses. A total of 26 patients were treated, including 17 patients with advanced colorectal cancer, and there was a partial response in seven of these mostly 5-FU refractory patients (giving a response rate of 40%). Multicentre phase II and III studies are ongoing, with recommended doses of 85 mg m-2 for oxaliplatin and 200 mg m-2 for CPT-11 being administered to patients every 3 weeks. Other planned studies include investigation of the safety and efficacy of oxaliplatin in advanced pancreatic cancer, alone or in combination with 5-FU. Oxaliplatin with CPT-11 or gemcitabine will also be studied in this indication.
OTHER INDICATIONS Oxaliplatin should also be considered for the treatment of other neoplastic conditions. A phase 1/11 trial looked at oxaliplatin as monotherapy in the treatment of heavily pretreated patients with refractory/relapsed intermediate and low-grade non-Hodgkin's lymphoma (Rotarski et al, 1993) . Patients (n = 22) had previously been treated with a median of two therapeutic regimens, and were started on a dose of 65 mg m-2 of oxaliplatin. Treatment was given every 3 weeks, and the dose was increased to 130 mg m-2. There were nine responders, giving an overall response rate of 41%. All of the responders were patients with low-grade non-Hodgkin's lymphoma (n = 15). The median response duration was 14 months (range 3-40 months) and median progression-free survival was 12 months.
In metastatic breast cancer, there were three responses to oxaliplatin as a single agent in a phase I trial. In a pilot phase II study, Garufi et al (1997) found that oxaliplatin, 130 mg m-2 administered every 3 weeks, given to 14 anthracycline-resistant patients with metastatic breast cancer resulted in a partial response in three patients.
There is also an ongoing phase I/II trial evaluating the safety and efficacy of oxaliplatin (130 mg m-2 on day 1) in combination with navelbine (22-34 mg m-2 on days 1 and 8), given every 3 weeks to 45 patients with non-small-cell lung cancer (Monnet et al, 1998 
CONCLUSIONS
The results of all of these trials are eagerly awaited, but it is clear from data already available that oxaliplatin is a highly active agent in the treatment of colorectal cancer and advanced ovarian cancer. It is an ideal candidate for use in combination with many of the well-established and new anti-cancer drugs, often resulting in clinical synergy or additive effects. There are also promising early results in the indications of non-Hodgkin's lymphoma, breast and non-small-cell lung cancers. It is now in the hands of oncologists to ensure that oxaliplatin is developed to achieve its full potential.
